➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Dow
Harvard Business School
Medtronic
Mallinckrodt

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FARXIGA

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Farxiga

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02371187 ↗ Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training? Recruiting AstraZeneca Phase 2 2015-06-01 Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin. Recent data (animal and human) suggest that metformin may attenuate the favorable benefits of exercise training. In light of the physiological mechanism of Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that rather than inhibit, it will augment the favorable adaptations to exercise training.
NCT02371187 ↗ Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training? Recruiting Christopher Bell Phase 2 2015-06-01 Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin. Recent data (animal and human) suggest that metformin may attenuate the favorable benefits of exercise training. In light of the physiological mechanism of Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that rather than inhibit, it will augment the favorable adaptations to exercise training.
NCT02372955 ↗ Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes Recruiting Gulf Regional Research & Educational Services, LLC Phase 4 2015-02-01 Dapagliflozin has been shown to lower clinic systolic and diastolic blood pressure in patients with type 2 diabetes mellitus. The exact mechanism(s) by which dapagliflozin lowers clinic SBP is unknown. The primary objective of the study is to determine the effect of dapagliflozin , 10 mg daily, on parameters of arterial stiffness: aPWV, augmentation index (AI), 24-hour blood pressure patterns, SBP, and pulse pressure. Urinary sodium excretion, and Intravascular volume status will be recorded. The study will involve 21 subjects for a duration of 16 weeks.
NCT02518945 ↗ Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes Recruiting University at Buffalo Phase 3 2015-08-01 This is a single center, prospective, randomized, double blinded placebo controlled study conducted I patients with type 1 diabetes.The aim of this study is to examine the additive effects of GLP-1 agonist and SGLT2 inhibitor in patients with type 1 diabetes in terms of possible improved glycemic control, reduced glycemic variability, reduced insulin dosages, additional effects of weight loss and blood pressure reduction.
NCT02520518 ↗ Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss? Recruiting AstraZeneca Phase 2 2015-08-01 Th mechanism of action of dapagliflozin is via sodium-glucose co-transporter 2 (SGLT2) inhibition. Sodium-glucose co-transporter 2 inhibition is associated with moderate weight (fat) loss, in addition to other health benefits, including decreased blood pressure, decreased inflammation, and decreased oxidative stress. It is unclear as to whether these health benefits are due to SGLT2 inhibition per se, or as a secondary effect of weight loss.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Farxiga

Condition Name

Condition Name for Farxiga
Intervention Trials
Diabetes Mellitus, Type 2 10
Type 2 Diabetes Mellitus 2
Diabetes Mellitus Type 2 2
Weight Loss 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Farxiga
Intervention Trials
Diabetes Mellitus 19
Diabetes Mellitus, Type 2 16
Diabetes Mellitus, Type 1 4
Heart Failure 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Farxiga

Trials by Country

Trials by Country for Farxiga
Location Trials
United States 45
Canada 2
Brazil 2
Qatar 1
Russian Federation 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Farxiga
Location Trials
Texas 10
New York 5
Missouri 5
Colorado 4
California 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Farxiga

Clinical Trial Phase

Clinical Trial Phase for Farxiga
Clinical Trial Phase Trials
Phase 4 17
Phase 3 3
Phase 2 8
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Farxiga
Clinical Trial Phase Trials
Not yet recruiting 19
Recruiting 16
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Farxiga

Sponsor Name

Sponsor Name for Farxiga
Sponsor Trials
AstraZeneca 13
The University of Texas Health Science Center at San Antonio 8
Christopher Bell 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Farxiga
Sponsor Trials
Other 46
Industry 18
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Boehringer Ingelheim
Express Scripts
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.